
James Christie joins Oxford BioMedica as manufacturing head
pharmafile | February 22, 2011 | Appointment | Manufacturing and Production | James Christie, Oxford BioMedica, appointment, manufacturing and production
UK gene therapy company Oxford BioMedica has appointed James Christie as its first head of manufacturing.
It following the firm’s decision to acquire a manufacturing facility in Oxford, UK from RecipharmCobra Biologics.
John Dawson, chief executive of Oxford BioMedica, said: “James is a highly-skilled addition to the senior management team at Oxford BioMedica. His operational and technical leadership will be instrumental as we bring our recently acquired proprietary manufacturing facility into operation during 2012 and seek to implement improved processes at increased scale for late stage clinical development.”
James has over 30 years of experience in the biopharmaceutical industry, most recently at BTG where he served as Operations Director.
He began his career in the biopharmaceutical industry in 1980 and worked with GlaxoSmithKline, Celltech Group and Centocor, before joining Therapeutic Antibodies in 1998.
When Therapeutic Antibodies merged with Proteus International to create Protherics in 1999, James was appointed to the Board with responsibility for manufacturing, quality, process development and technical support operations in Australia, the UK and the US. Protherics was subsequently acquired by BTG in 2008.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut …






